Inhibition of human pancreatic lipase by aspirin: experimental and in silico study
The Ukrainian Biochemical Journal · 20.04.2026 · 98 (2) · 40-50
DOI: 10.15407/ubj98.02.040 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Ukrainian Biochemical Journal, online erschienen am 20.04.2026. Verfasst von R. T. Altaee, und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Excessive accumulation of adipose tissue is a hallmark of obesity as a critical factor in the development of numerous chronic medical problems. Pancreatic lipase (PLase), which controls the absorption of fats in the intestine, has gained significance as a target in anti-obesity therapy. This study aimed to evaluate the potential effects of Aspirin as a PLase inhibitor and a weight-loss agent compared to the commonly used anti-obesity drug Xenical. Pancreatic lipase was purified 28.5-fold from the plasma of obese male volunteers using ion-exchange chromatography. Enzyme activity was evaluated using p-nitrophenyl butyrate as a substrate. The kinetic analysis of Aspirin effect on purified enzyme activity revealed a competitive inhibition mechanism with Ki of 24.3 mM. In vivo studies were performed using 20 male Wistar rats randomly divided into four equal groups provided with: 1 – control conditions; 2 – high-fat diet (HFD) for 12 weeks; 3 – HFD and Xenical orally (10 mg/kg BW daily); 4 – HFD and Aspirin orally (14.4 mg/kg BW daily). In an HFD group, increased animals body weight and elevated PLase activity in plasma compared to the control were demonstrated. Treatment with both Aspirin and Xenical resulted in a significant decrease in body weight and PLase activity compared with untreated HFD rats. Molecular docking of Human Pancreatic lipase-related protein 1 (PDB ID: 2PPL) binding with Aspirin and Xenical showed the values of binding energy (ΔG) 5.4 and -4.4 kcal/mol, respectively, indicating a stronger protein interaction with Aspirin compared to Xenical. This combined study reinforces the conclusion that Aspirin has the potential to be a novel anti-obesity agent. Keywords: anti-obesity effect, aspirin, human pancreatic lipase-related protein 1, in silico study, kinetic inhibition analysis, obesity, pancreatic lipase, Xenical
Zitieren
APA
Altaee,, R. T., Aldabbagh, M. G., & Al-Abbasy, O. Y. (2026). Inhibition of human pancreatic lipase by aspirin: experimental and in silico study. The Ukrainian Biochemical Journal, 98(2), 40-50. https://doi.org/10.15407/ubj98.02.040
Vancouver
Altaee, RT, Aldabbagh MG, Al-Abbasy OY. Inhibition of human pancreatic lipase by aspirin: experimental and in silico study. The Ukrainian Biochemical Journal. 2026;98(2):40-50. doi:10.15407/ubj98.02.040
BibTeX
@article{Altaee2026,
author = {Altaee,, R. T. and Aldabbagh, M. G. and Al-Abbasy, O. Y.},
title = {Inhibition of human pancreatic lipase by aspirin: experimental and in silico study},
journal = {The Ukrainian Biochemical Journal},
year = {2026},
volume = {98},
number = {2},
pages = {40--50},
doi = {10.15407/ubj98.02.040}
}
EUVIMED